ResMed, In A Buy Zone, Stays Flat After Handily Beating Earnings Views

Blockhead
01-31

ResMed (RMD) stock traded sideways late Thursday after the medtech company reported adjusted earnings of $2.43 per share on $1.28 billion in fiscal second-quarter sales.

X NOW PLAYING How To Buy Stocks: Double-Bottom Chart Pattern

Analysts polled by FactSet expected the CPAP maker to earn $2.32 per share and $1.27 billion in sales. Sales increased 10%, while earnings rose more than 29%.

ResMed didn't provide guidance for the year. The Street projected EPS of $9.41 and $5.12 billion in sales.

In after-hours trades, ResMed stock was roughly flat at 257.65. Shares broke out of a double-bottom base with a buy point at 252.36, according to MarketSurge.

More to follow.

YOU MAY ALSO LIKE:

Thermo Fisher Scientific Gaps Up And Nears A Buy Point On Strong Earnings Beat

Teva Stock Dives 14%. 'We're Victims Of Our Own Success,' Says CEO.

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

Follow Premarket And After-The-Open Action With IBD Experts

Find Today's Best Growth Stocks To Watch With IBD 50

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10